Neurophet's AI-driven software, Neurophet AQUA AD Plus, has received FDA 510(k) clearance, furthering its commitment to transforming Alzheimer's diagnostics.

Neurophet has appointed Dr. Lawrence N. Tanenbaum as its Scientific Advisor to bolster its AI-driven neuroimaging capabilities and global partnerships.

In a groundbreaking partnership, Neurophet collaborates with VHIR to enhance AI diagnoses for multiple sclerosis, employing advanced MRI analysis for improved patient outcomes.

Neurophet, a Korea-based artificial intelligence company specializing in brain disease diagnostics and therapeutics, said it will showcase its flagship neuroimaging analysis solutions at the upcoming Alzheimer’s Association International Conference (AAIC) 2025, to be held in Toronto, Canada, from Ju

The FDA cleared an extended version of Neurophet AQUA that uses AI to count and measure MS brain lesions on MRI scans.

Dr. Franceschi currently serves as Director of Dementia Imaging and Director of Molecular Neuroimaging at Northwell Health, where she has led advances in brain MRI and PET imaging technologies Neurophet aims to strengthen the clinical evidence for its key products and accelerate its...

Neurophet, an AI company specializing in brain disorder solutions, partners with Elevate Clinic in the U.S. to enhance its presence in the market.

Provides solutions for analyzing brain atrophy and white matter hyperintensities, as well as monitoring side effects associated with Alzheimer's disease treatments Secures a key reference site at a U.S. medical institution specializing in neurological disorders, accelerating product...

Neurophet will present its AI-powered brain imaging solution, Neurophet AQUA AD Plus, at AAIC 2026, forging new global partnerships with pharmaceutical companies.

Diagnostika roztroušené sklerózy (RS) bývá někdy velmi složitá a vyžaduje pečlivé oko zkušeného radiologa. Jihokorejská technologická společnost Neurophet proto spojila síly s prestižním španělským vý...

(TrendHunter.com) Neurophet, a specialist in artificial intelligence applications for neurological conditions, has expanded its cooperative research efforts — known as the Enhanced Dementia Diagnosis initiative...

Neurophet, a Korean AI-backed brain disease diagnosis and treatment developer, said Tuesday that it has signed a supply agreement with the National University of Singapore (NUS) and Singapore General Hospital (SGH) for its PET imaging analysis software, Neurophet SCALE PET.Under the agreement, Neuro

Neurophet, a Korea-based artificial intelligence (AI) company specializing in brain disease diagnosis and treatment, said Tuesday that it signed a research collaboration agreement with F. Hoffmann-La Roche Ltd, to advance AI-powered neuroimaging solutions.The agreement builds on ongoing data-sharing

Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD Company accelerates partnerships with global pharmaceutical companies and neurology KOLs to drive collaboration in Alzheimer's disease clinical imagi...

- Showcased core technology and products for personalized tDCS at the conference in Kobe, Japan - Presented clinical outcomes in disorders of consciousness, upper extremity function in patients with sub-acute and chronic stroke, and post-stroke dysphagia…

Neurophet’s AI brain image analysis technology improves time and cost efficiency for drug development Aims to create business opportunities with global pharmaceutical companies SEOUL, South Korea, May 31, 2024 /PRNewswire/ — Neurophet, an artificial…

Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet’s leadership in AI-based Alzheimer’s disease imaging analysis Advanced analysis of neuroimaging features associated with cerebral microbleeds and edema supports imaging-based clinical decision-making and accelerates U.S. market expansion SEOUL, South Korea, Feb. 6, 2026 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial […]

Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer’s disease treatments Highlighted clinical value of Neurophet AQUA AD…To accelerate efforts across healthcare institutions in Southeast Asia SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company […]

Demonstrated brain imaging analysis solutions, including ‘Neurophet AQUA AD,’ which enables monitoring of adverse effects associated with Alzheimer’s disease treatments Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session SEOUL, South Korea, Dec. 5, 2025 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence […]

Neurophet has entered a collaboration to advance software that uses AI to examine brain MRI scans for signs characteristic of MS.

Neurophet has entered an MoU with the ALZ-NET to facilitate imaging monitoring infrastructure for therapies related to Alzheimer’s disease.

Neurophet wins FDA clearance for AQUA AD Plus, strengthening its U.S. strategy as AI imaging becomes central to Alzheimer’s treatment decisions. Read more.

Providing Neurophet AQUA capable of analyzing brain atrophy and white matter degeneration... Securing meaningful clinical reference SEOUL, South Korea, July 2, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain dis...

Neurophet's cutting-edge AI software, Neurophet AQUA, is now available at Raffles Medical in Singapore, enhancing diagnostic capabilities for brain disorders.